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lower blood pressure and serum Na and were more likely to have had a recent HF hospi- 
talization (all P < 0.001). Results. Shown below are 1-year Kaplan-Meier ates and Cox 
model hazard ratios (CRV:PBO): 
Spironolactone No Spironolactone 
PBO CRV Hazard PBO(n=908) CRV (n=936) Hazard ratio 
(n=225) (n=220) ratio 
All-cause 19.1% 11.4% 0.65 18.4% 11.3% 0.65 
mortality 
Death or 39.3% 26.3% 0.63 37.5% 25.4% 0.70 
hospitalization 
for worsening HF 
Death or 41.6% 29.1% 0.61 41.6% 30.4% 0.75 
cardiovascular 
hospitalization 
Death or any 47.2% 38.4% 0.76 53.3% 42.1% 0.76 
hospitalization 
CRV reduced the risk of a major clinical event in patients on spironolactone to an extent 
similar to that seen in patients not on spironolactone. 
Conclusion. These data indicate that the morbidity and mortality of patients with severe 
HF receiving drugs that interfere with more than one neurohormonal target can be 
reduced substantially with further neurohormonal antagonism (with CRV). 
1157-160 Beta-Blocker Utilization in Heart Failure Patlenta: 
Experience From a Heart Failure Clinic 
Ritash Gueta, W.H. Wilson Tang, James B. Young, Cleveland Clinic Foundation, 
Cleveland, Ohio. 
Background: Beta blockers (BB) reduce mortality in heart failure (HF) patients. Though, 
well tolerated in clinical trials, utilization rates in clinical settings have not been studied. 
Methods: Retrospective analysis of 500 consecutive HF patients presenting to a HF 
clinic between 3/01 to 5/01 (mean age 61, 69% males, 53% ischemic, mean LVEF 27%). 
Chi-square test was utilized for subgroup analysis. 
Results: 75% of patients had been given a BB trial and 69% were currently on BB. The 
use of BB was more in moderate (LVEF 20 - 40, n=236) compared to mild (LVEF >40, n 
= 92) and severe (LVEF <20, n =141) HF (73% vs. 60% and 65%, p=0.04). BB use also 
decreased with worsening NYHA class of HF symptoms (I 76%, II 72%, III & IV 60%, 
p=0.01). No difference in BB use by gender was seen (68% in males vs. 71%, p=0.5). 
Discontinuation rate was 6.8% and was not influenced by NYHA class (p=0.3). Down 
titration was required in 5.2%. Side effects leading to stopping or down titration, included 
dizziness (3.2%), fatigue (2.8%), hypotension (2.6%), bradycardia (2.0%), and others 
(1.4%). A contraindication could be identified in 44% of patients never tried on BB with 
respiratory disease being the most common in 33%, uncompensated state in 7%, A-V 
block in 1% and hypotansion in 1.6%. Subgroup of diabetics had lower BB use than non 
diabetics(60% vs 73%, p=0.02) with more contraindications (36% vs. 18%, p < 0.01 ) and 
worse NYHA class (p= 0.03) though LVEF was similar (p=0.5). Trend towards lower BB 
use was seen in elderly patients (age >74) than younger patients (61% vs. 71%, p=0.06) 
but there was no difference in rate of contraindication to BB(29% vs. 23%, p= 0.1 ). 
Conclusion: High utilization rates for BB (69% current usage) can be achieved with an 
aggressive approach to initiating BB therapy. Respiratory diseases are the most common 
reason of not initiating BB therapy. Diabetics and elderly patients are less likely to be on 
BB. Diabetics tend to have more contraindications to BB and worse NYHA class than 
non diabetics, which may explain lower use of BB in them. Eldedy patients do not show 
this trend and lower use in this group needs further investigation. 
POSTER SESSION 
1158 
Chagas,  Diabetes,  Sc leroderma,  and 
Cardiomyopathy 
Tuesday, March 19, 2002, 9:00 a.m.-11:00 a.m. 
Georgia World Congress Center, Hall G 
Presentation Hour: 9:00 a.m.-10:00 a.m. 
1158-146 Phosphoramidan Ameliorates the Functional Sequelae 
of Experimental  Chronic Chagasic Cardiomyopathy 
Madhulika Chandre, Herbert B. Tanowitz. Vitally Shtufln, Jamshid Shirani, Albert Einstein 
College of Medicine, Bronx, New York. 
Background. Trypanosoma crozi, the etiologic agent of Chagas' disease, is an important 
cause of chronic cardiomyopathy. Coronary microvascular spasm, in part mediated by 
endothelin-1, appears to play a significant role in the pathogensis of experimental chronic 
chagasic cardiomyopathy. Aim. We sought to assess if the administration of an endothe- 
lin inhibitor, phosphoramidan, could influence the severity of cardiomyopathy in mice 
infected with T. cruzL Methods. Therefore we infected cdl mice (n=21) with 104 trype- 
mastigotes of the Brazil strain of "K cruzi. Of these, 8 were treated with phosphoramidan. 
An additional 8 uninfected littermatas ewed as controls (C), 3 of which received phos- 
phorarnidan. All mice (n--29) survived and were evaluated at 150 days post infection by 
transthoracic echocardiography. Left ventricular (LV) end diastolic diameter (EDD), rela- 
tive wall thickness (RW'F), and fractional shortening (FS) were measured. Right ventricu- 
lar (RV) size was assessed semi-quantitatively on a scale of 0-3. Results. There was no 
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effect of phosphoramidan on LV EDD, RWT, FS or RV in uninfected (C) mice. Infected, 
untreated mica (INF) had increased LV EDD (3.2±0.1 v 2.8±0.1mm, p<0.05), along with 
reduced FS (39±2 v 57±1%, p<0.05) and RWT (0.4±0.0 v 0.5±0.0, p<0.05), compared 
with C. Treatment with phosphoramidan reduced the magnitude of these changes, such 
that the infected, phcaphoramidan treated mica (INF+P) had no significant differences in 
LV EDD (2.9±0.1 v 2.8±0.1mm), RWT (0.5±0.1 v 0.5±0.1), and FS (57±2 v 50¢4%) com- 
pared with C mice. Similarly, RV was larger in INF compared with both C and INF+P mice 
(2.1¢0.3 ,) 1.5±0.4, INF v INF+P respectively, p<0.01). Conclusion. These data indicate 
that phosphoramidan ameliorates the functional sedulae of experimental chronic cha- 
gasic cardiomyopathy. 
1158-147 Molecular Epidemiology of Cardiac Actin Gene 
Mutations in Dilated Cardlomyopathy 
Ronald Zoltv, G. Passarino, M. R. Taylor, A. Moss, L. Mastroni, M. R. Bristow, UCHSC, 
Denver, Colorado, Stanford University, Palo Alto, California. 
Background: Dilated cardiomyopathies (DCM) are characterized by a large vantricular 
dilatation and impaired systolic function. There is a strong genetic component in DCM, 
estimated to be present in approximately 20-30percent of cases. Mutations in axons 5 
(Arg312His) and 6 (Glu361Gly) of cardiac actin gene (ACTC) have been reported in two 
families with DCM. Methods: In order to evaluate prevalence and characteristics of 
ACTC gene mutations in DCM, 62 patients from different ethnic backgrounds were stud- 
ied: 17 with sporadic DCM, 45 with familial DCM (belonging to 31 unrelated families). 
Two patients with ischemic heart disease were used as controls. Genomic DNA was 
extracted from blood or explanted heart tissue using standard procedures. PCR products 
were generated from all 6 exons of the ACTC gene, allowing the inclusion of the exon,' 
intron boundaries. Mutation analysis of all 6 axons was performed using denaturing high 
performance liquid chromatography (DHPLC) and sequence analysis. Results: No muta- 
tion was found in any of the six ACTC exons. A single nuclectide pelymorphism was 
detected by DHPLC, and confirmed by sequence analysis in intron 5 (C-62T). Conclu- 
sions: ACTC mutations do not seem to be associated with DCM in our large population of 
familial and sporadic DCM. ACTC mutations appear to be infrequently associated with 
DCM 
1158-148 Noninvseive Asselmment of Coronary Flow Reserve 
Impairment in Patients With Systemic Sclerosis 
Roberta Montisci. Paolo Colonna, Massimo Ruscazio, UJun Chen, Carlo Caiati, Pietro 
Gareu, Giuseppe Passiu, Alassandra Vacca, Alessandro Mathieu, Sablno Ilicato, 
Department of Cardiovascular and NeuroL Sciences, Cagliari, italy, Institute of 
Rheumathology, Cagliari, Italy. 
Background. Systemic sclerosis (SSc) is a chronic connective tissue disorder of 
unknown etiology, characterized by cutaneous and visceral tissue fibrosis with arteitolar 
and capillary ischemic dysfunction. The pathogenesis of the cardiac lesion in SSc is con- 
troversial, but the primary disorder of microvasculature with diffuse artsriolar and capil- 
lary lesions could precede any fibrosis, thus causing ischemic disorder to the head. CFR 
is used to evaluate coronary microcirculation, and has been already employed to investi- 
gate myocardial microcirculation impairment in SSc. Previous invasive studies have 
demonstrated that coronary flow reserve (CFR) is impaired in patients (pts) with 
advanced SS and cardiac involvement. We tested the hypothesis that CFR can be early 
impaired in patients with systemic sclerosis without cardiac involvement and whether 
CFR impairment is correlated to the cutaneous subset. 
Methods. We studied 26 patients with SSc without clinical evidence of heart disease, (14 
with diffuse form and 12 with localized form of SSc) and 22 control group patients, 
matched in age and gender. We evaluated CFR in the left anterior descending coronary 
artery (LAD) with a new non-invasive method : contrast (Levovist) enhanced transtho- 
racic Doppler (CEE-TTE) during adenosine infusion. The pulsed wave Doppler of blood 
flow velocity was recorded in the LAD at rest and after maximum vasodilaflon by adenos- 
ine infusion (140 mcg/Kg/min in 5 minutes). 
Results: In patients with SSc, without clinical evidence of heart disease, CFR was 
impaired (2.65:t:0.63 vs 3.29~0.52 in controls, p < 0.0005). A significantly, greater per- 
centage of SSc patients had reduction of (_< 2.5) CFR compared to controls ( 48% vs 
4.5%, p=0.003). Left ventricular mass and ejection fraction were not statistically different 
in the two groups. A non-significant trend between mean CFR and the severity and dura- 
tion of the disease was also observed. 
Conclusion. in this cross-sectional study we demonstrated that CFR is early reduced in 
patients with SSc and seems to be correlated to the extension of the cutaneous subset of 
the disease. A reduction of CFR could be an early sign of cardiac involvement in sys- 
temic sclerosis. 
1158-149 Clinical Course of Dilated Cardiomyopathy in 
Asymptomatic Patients Long-Term Treated With Beta- 
Blocking Agents: The Heart Muscle Disease Registry of 
Trieste 
Andrea Di Lenarda, Gastone Sabbadini, Gererdina Lardieri, Mauro Driussi, Elisa Camiel, 
Laura Vitali Serdoz, Stafano Pangher, Gianfranco Sinagra, Department of Cardiology, 
Trieste, Italy, Department of Medicine and Geriatrics, Trieste, Italy. 
No conclusive data are available on long-term effects of adding a beta-blocker (BB) to 
ACE-inhibitor (ACE-I) therapy in asymptomatic patients with dilated cardiomyopathy 
(DC). 
Among 447 DC patients consecutively enlisted in the Heart Muscle Disease Registry of 
Trieste between 1986 and 2000, 307 (68.7%) had HF symptoms (NYHA II-IV, Group 1) 
while 140 (31.3%) were asymptomatic (NYHA I, Group 2) at enrolmect, in Group 2, a 
previous history of HF was present in 71 patients (50.7%)(Group 2a) and absent in 69 
(49.3%)(Group 2b). 
